Company intelligence / Profile preview

PinCell

Milan, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

PinCell has demonstrated in vivo efficacy for its monoclonal antibody (PC111) in blocking blister formation in skin disease models without immunosuppression; PC111 has Orphan Drug Designation in Pemphigus (EMA), with plans for FDA Orphan/Breakthrough applications. PC111 ameliorates features of SJS/TEN in in vivo models[4][1].

Therapeutic areas: Dermatology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Scinai Immunotherapeutics Ltd. (option agreement to acquire; collaboration on PC111, grant application[4])Sofinnova Partners (seed investor[1])

Beyond the preview

Go deeper on PinCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PinCell.

Explore the full profile